clinical trial results
-
October 18, 2021
Novel Car-T Shows ‘Promising Early Signs of Clinical Efficacy’ for Diffuse Midline Gliomas Bookmark
George Lundberg, MDHealio outlines results from a Stanford University study suggesting that a type of treatment known as CAR T-cell therapy is promising for children with diffuse midline gliomas. The treatment is still in an early phase of testing in humans.
.
-
January 29, 2021
Efficacy and Safety of Sorafenib Plus Vitamin K Treatment for Hepatocellular CarcinomA: A Phase II, Randomized Study Bookmark
George Lundberg, MDThis scientific research paper published in the journal Cancer Medicine reports that the drug sorafenib has shown some effectiveness against hepatocellular carcinoma in a clinical trial, and that adding vitamin K2 enhanced that effectiveness.
.
-
May 30, 2020
Overall Survival Benefit Shown for Maintenance Olaparib in Ovarian Cancer Bookmark
George Lundberg, MDArticle from The ASCO Post curated by Editor in Chief George Lundberg, MD, who notes:
Clinical trial results have shown a 13-month overall survival benefit from maintenance therapy—treatment to prevent or delay recurrence—with olaparib for advanced ovarian cancer.Go to full article published by The ASCO Post.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
May 30, 2020
No OS Boost With Opdivo in Recurrent Glioblastoma Bookmark
George Lundberg, MDArticle from MedPage Today curated by Editor in Chief George Lundberg, MD, who notes:
In a large clinical trial for recurrent glioblastoma, treatment with the drug nivolumab, a PD-1 inhibitor, performed no better than standard-of-care treatment with the drug bevacizumab.Go to full article published by MedPage Today.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
May 30, 2020
Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study Bookmark
George Lundberg, MDResearch paper from the Journal of Clinical Oncology curated by Editor in Chief George Lundberg, MD, who notes:
Eighty percent of ovarian cancers are first diagnosed after they have already spread. In the clinical trial discussed in this paper, a combination of two checkpoint inhibitor immunotherapy drugs showed only modest benefit in advanced ovarian cancer.
Go to full paper published in the Journal of Clinical Oncology.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
February 22, 2020
‘Unprecedented’ Responses to Cisplatin/Gemcitabine in BRCA-Mutated Advanced Pancreatic Cancer Bookmark
George Lundberg, MDArticle from The ASCO Post curated by Editor in Chief George Lundberg, MD, who notes:
A treatment that combines two drugs can be beneficial for some patients who have advanced pancreatic cancer with BRCA mutations.
Go to full article published by The ASCO Post.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
January 6, 2020
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer Bookmark
George Lundberg, MDResearch paper from The New England Journal of Medicine curated by Editor in Chief George Lundberg, MD, who notes:
These clinical trials results suggest that the drug niraparib is superior to platinum-based chemotherapy for people with newly diagnosed advanced ovarian cancer.
Go to full paper published in The New England Journal of Medicine.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
December 26, 2019
Triplet Regimen Offers Improved Outcomes in BRAF-Mutant Colorectal Cancer Bookmark
George Lundberg, MDArticle from Cancer Network curated by Editor in Chief George Lundberg, MD, who notes:
In a phase III clinical trial, a triple-drug therapy nearly triples overall survival for patients with colorectal cancer.
Go to full article published by Cancer Network.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
December 13, 2019
PARP Inhibitors Center Stage for Ovarian Cancer Bookmark
George Lundberg, MDArticle from Medscape curated by Editor in Chief George Lundberg, MD, who notes:
Drugs known as PARP inhibitors can improve progression-free survival (PFS) in many patients with advanced ovarian cancers.
Go to full article published by Medscape.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
December 2, 2019
Niraparib Maintenance Treatment Improves Time Without Symptoms or Toxicity (TWiST) Versus Routine Surveillance in Recurrent Ovarian Cancer: A TWiST Analysis of the ENGOT-OV16/NOVA Trial Bookmark
George Lundberg, MDResearch paper from the Journal of Clinical Oncology curated by Editor in Chief George Lundberg, MD, who notes:
Niraparib substantially improves TWIST (time without symptoms or toxicity) over no treatment in recurrent epithelial ovarian cancers, even moreso if positive for gBRCAmu.
Go to full paper published in the Journal of Clinical Oncology.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.